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We review the commonly occurring persistent pesticides and industrial chemicals in breast milk. These chemicals are dichlorodiphenyl
trichloroethane as dichlorodiphenyl dichloroethene dieldrin, chlordane as oxychlordane, heptachlor, polychlorinated biphenyls, polychlorinated diben-
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Introduction
Any xenobiotic that the nursing mother
absorbs and circulates may contaminate
her breast milk; this is documented for
components ofbeverage alcohol (1-3) and
tobacco smoke (4), pharmaceuticals (5),
persistent pesticides, industrial chemicals,
volatiles, and metals (6). Pharmaceuticals
have been treated in other reviews (5,7),
and the data for the volatiles and the met-
als are sparse, so what follows is a review of
the commonly occurring persistent pesti-
cides and industrial chemicals in breast
milk, and worked examples ofthe kinds of
pharmacokinetic assumptions and calcula-
tions necessary for both setting regulatory
limits and for estimating the cancer risk to
the child. This material is condensed from
three papers, which contain more back-
ground and more complete references
(8-10). Although commonly occurring
pesticides and industrial chemicals have
been banned or were never produced
intentionally, our research topic is not
archaic, as there have been inadvertent
exposures to agents that involved contami-
nation ofhuman milk, and several chemi-
cals are part ofthe waste stream or are still
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present in large amounts in the environ-
ment. Thus, human exposure will likely
continue. Years ofsmall daily doses at lev-
els that contaminate food below the limits
ofanalytic detection can result in measur-
able levels in fat tissue, with no recollection
on the part of the individual that special
exposure has taken place. The considera-
tions necessary to evaluate the hazards
from these agents are similar to those that
will come up with any agent. In particular,
assumptions regarding the pharmacokinet-
ics of the agents are inherent in any of
these evaluations, and the conclusions may
depend heavily on the kinds of assump-
tions made. All the chemicals discussed are
present in trace amounts in a substantial
fraction of the breast milk of U.S. women
with no obvious known source to account
for their presence. There also have been
accidental, somewhat higher exposures,
and those situations will be presented for
context.
Chemical Contaminants
DDT. Dichlorodiphenyl trichloro-
ethane enjoyed widespread use from its
introduction in the 1930s until its ban by
the U.S. Environmental Protection Agency
(U.S. EPA) in 1972. DDT and its deriva-
tives are stable in the environment and
remain active long after initial application.
Once in the food chain, it resists ultimate
metabolism and bioconcentrates in preda-
tors (11). Among those predators is man,
and during the 1960s, evidence accrued
that residues of DDT or its stable metabo-
lites, especially DDE (dichlorodiphenyl
dichloroethene), were detectable with very
high prevalence in human fat tissue (as a
consequence of their fat solubility) and
human milk (as a consequence of its fat
content).
Laug (12) reported the presence of
DDT in human milk in 1951. Since then,
there have been many reports of occur-
rence, some information on factors that
vary with the amount ofchemical present,
and few reports of directly attributable
morbidity. Generally, African-Americans
have higher DDT levels than whites (13),
levels go up with age (14), and smokers
have higher levels than nonsmokers (15).
Levels decline over the course oflactation;
levels after 6 months of breast feeding are
about 80% of those at the beginning.
Women have lower levels after having
breast fed a previous child; pregnancy per
se lowers levels very little (14).
While reports of morbidity have been
lacking, several findings that are plausibly
effects of DDT contamination have been
reported at least once. O'Leary et al.
reported that low birth weight premature
babies have higher DDE in whole blood
than term infants ofhigher normal birth
weight (16). There is a report from Israel
showing higher levels in women with pre-
mature delivery (17). Rogan et al. reported
that women with higher DDE levels breast
feed for a shorter length of time (18); in
the same data, however, there was no asso-
ciation with birthweight or with increased
incidence of illness (taking into acccount
other factors such as smoking).
Heptachlor. Heptachlor is a polyhalo-
genated cyclodiene pesticide that is rou-
tinely detected in human milk samples in
the United States; it is metabolized to an
intermediate epoxide form and is then
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stable in human tissue. Savage et al.
reported that, in 1975, there were
detectable amounts ofheptachlor in about
60% of breast milk samples from 1046
women volunteers recruited from a proba-
bility sample of U.S. hospitals (19). Limit
ofdetection at that time was 1 ppb (whole
milk); depending on the region of the
country, medians were around 0.25 ppm,
and 95th percentiles ranged from 0.46 to
1.29 ppm (fat basis, assuming 2.5% fat).
Heptachlor was withdrawn from most
uses in 1978 because ofits persistence and
bioaccumulation and because it is a car-
cinogen in the laboratory. However, the
state of Hawaii had an exemption for use
on pineapples. In January 1982, the
Hawaii state health department found hep-
tachlor in routine analyses ofcow's milk at
levels above the 0.3 ppm (fat basis) that
was permitted as a residue. The contamina-
tion was traced to the practice offeeding
dairy cows green chop from the pineapple
fields. Pineapples are subject to mealybug
damage, and mealybugs live commensally
with ants. It had long been the practice to
kill the ants with one ofthe persistent pes-
ticides. Pineapple leaves and other materi-
als went into the green chop. No plant that
had been sprayed within a year was sup-
posed to be included; although heptachlor
does not degrade substantially, the plant
grows over that time and dilutes the
residue. Retrospective testing ofgreen chop
samples showed that heptachlor was pre-
sent as far back as June 1981. It could not
be documented whether milk contamina-
tion had gone back that far. Results ofrou-
tine tests were supposedly negative, but the
chromatograms had been discarded and
were not available for suspicious review
(20).
The Hawaiian mothers' milk showed
detectable heptachlor epoxide; the median
ofapproximately 200 samples from August
1981 to January 1983 was about 0.1 ppm,
with 95th percentile 0.35 ppm fat basis
(21). The 1979 to 1980 average in the
same lab had been 0.035 ppm (22,23).
Thus the levels had increased 3-fold, but
into the range ofexpected values on the
mainland. The tolerance level for residues
in food had been set at 0.3 ppm fat on the
basis of the technology available to detect
the substance in the 1960s, but it was possi-
ble in 1981 to detect at 0.1 ppm routinely
and lower on a research basis. Application
ofeither number would result in a substan-
tial fraction ofwomen being advised not to
breast feed. However, it was not clearwhat,
ifany, benefit would accrue to the children,
since the tolerance levels were not based on
any known or suspected risk but rather on
the state ofthe art ofanalytic chemistry.
Thus far, there has not been morbidity
attributed to the Hawaiian heptachlor
exposure. There is preliminary evidence
that heptachlor epoxide levels in serum and
breast milk in 1989 to 1990 are higher on
Oahu than on the neighbor islands, and
that levels bear a relationship to current
milk consumption, presumably a surrogate
for milk consumption during the time of
the contamination (24).
In 1986, cow's milk in Arkansas was
found to be contaminated with heptachlor.
This time, the cows had been fed mash left
over from the fermentation ofgrain to pro-
duce ethanol for addition to gasoline (25).
Thus far, despite almost a thousand analy-
ses ofbreast milk samples, there is no evi-
dence that the contamination was
sufficiently severe to raise breast milk levels
in Arkansas higher than in the adjoining
southeastern states (26).
Chlordane. The simplest way in which
houses can be protected from termite infes-
tation is by application ofone ofthe persis-
tent cyclodienes such as chlordane; they can
be effective for 20 years. Chlordane had
widespread use as a termitocide. In 1970,
inadvertent injection ofchlordane into the
heating ducts ofa southwestern military
home resulted in air contamination when
the heat was turned on (27). Several inci-
dents like this happened over the next few
years; drench application under the slab or
ditch application combined with heating
ducts that were either in the slab or beneath
it resulted in unacceptably high levels when
the heat was used. Eventually, the U.S. Air
Force did studies in almost 500 dwellings
and found that while most values ranged
from nondetectable to about 40 pg/m3,
occasional values had ranged up to
260 Pg/m3. At the higher levels, people who
lived in the building had irritative symptoms
and noted a strong "organic" odor. The
symptoms abated and the air cleared when
repairs were made (28).
Breast milk levels increased for up to 5
years among those who lived in treated
houses (29). Chlordane or its metabolite,
oxychlordane, was one of the pesticides
found routinely in breast milk. Data from
the 1975 U.S. survey noted above (19)
show that about three-fourths ofa national
sample of women had oxychlordane
detectable in their milk at a sensitivity of 1
ppb whole milk basis. There are not reports
ofmorbidity from chlordane in the general
population.
PolychIorinatedBiphenyls, Polychlor-
inated Dibenzofurans, and Poly-
chlorinated Dibenzodioxins. Poly-
chlorinated biphenyls (PCBs) are a family of
compounds that share a paired phenyl ring
structure with various degrees ofchlorina-
tion. They were introduced in the 1930s as
a dielectric for cables, capacitors, and trans-
formers used in the electrical industry.
Other uses included microscope immersion
oil, the suspension vehicle for the pigment
in carbonless copy paper, fluid insulators in
a legion ofsmall electrical parts, cutting oils,
and occasionally dispersants forpesticides.
By 1966, Jensen was able to identify
peaks in his chromatograms ofhis wife's
breast milk, his child's hair, and a dead
North Sea eagle as PCBs (30). Because these
same peaks had been interfering in the chro-
matograms ofchemists in Europe and the
United States who were trying to document
the widespread extent of DDT contamina-
tion, it became clear that PCBs had become
ubiquitous contaminants like DDT.
In 1968, an epidemic of severe acne
among residents of Kyushu province in
Japan was traced to the use ofcooking oil
that had been contaminated by PCBs dur-
ing processing. Over 1000 people were
eventually diagnosed as having Yusho (oil
disease) by the local health authorities
(31). Yusho was essentially chloracne with
liver and nerve function abnormalities
along with alterations in fat metabolism.
PCBs appeared in the breast milk ofcases,
although levels were not remarkably differ-
ent from controls. Breast-fed children had
higher levels in their serum than bottle-fed
children. Follow up of children up to 9
years later, including some cases that were
reported to have been produced by breast
milk transmission alone, showed apathy,
lethargy, and soft neurological signs (32).
Chemical analysis at the time could do no
better than to show 2000 to 3000 ppm
total organic chlorine; subsequent analyses
showed that degradation ofthe PCBs had
taken place and that polychlorinated ter-
phenyls, quaterphenyls, and dibenzofurans
were present (33). The toxicity of these
compounds is similar in the laboratory to
that of PCBs; however, the dose at which
they are active is substantially lower.
Following Yusho, two lines ofresearch
were pursued through the 1970s: docu-
mentation of the degree of exposure of
human beings to PCBs and explication of
toxicity in the laboratory. The monitoring
literature is fairly consistent, showing a
very high to universal prevalence of
detectable PCB contamination in unse-
lected groups ofpeople. In the general pop-
ulation, levels go up with age and are
sometimes higher in African-Americans
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than whites. Thus far, no groups have reli-
ably higher levels except for persons who
work around PCBs and persons who regu-
larly consume sport fish from polluted
waters (commercial fish are regulated, and
are removed from the market ifthe amount
present exceeds the Food and Drug
Administration [FDA] action level).
In 1979, there was an outbreak ofacne
among school children in Taichung
province of Taiwan. Investigation pro-
ceeded much more rapidly than had been
the case inJapan 11 years earlier, and conta-
minated rice oil was again the vector
(34-36). Although the specific machine
was not identified, residue under the site of
a scrapped machine showed PCB-contami-
nated cooking oil. Over 2000 patients are
still followed by health authorities. The
symptoms, signs, and laboratory findings are
roughly similar to theJapanese outbreak.
Much of the toxicity in the Asian out-
breaks is likely because ofpolychlorinated
dibenzofurans (PCDFs), a thermal degra-
dation product of PCBs. Although these
chemicals occur in the rice oil mixtures at
levels I04below the PCBs, they are much
more toxic. PCDFs and polychlorinated
dibenzo-p-dioxins (PCDDs) have similar
physical and chemical properties. PCDFs
have one oxygen that bridges the phenyl
rings. The dioxins have two oxygens; the
most toxic of the dioxins are among the
most toxic substances known. PCDFs and
PCDDs occur in the environment from ill-
defined sources; possible sources include
contamination ofpesticides during manu-
facture, the bleaching process in paper
making, and combustion ofchlorine-con-
taining waste material. Both classes of
chemicals occur at low but detectable levels
in breast milksamples from persons without
known exposures.
RiskAssessmentandRegulation
Reference Dosefor the Mother. Since the
agents reviewed above occur as trace conta-
minants in the food supply, regulatory
agencies such as FDA must establish a con-
centration below which a class offoods can
still be sold, because permitting no
detectable residue is thought to cause great
economic hardship with little benefit for
public health. The FDA calls these concen-
trations action levels, and they are arrived atby
different methods depending on the toxic-
ity ofthe agents involved and the degree to
which they are avoidable or unavoidable
contaminants (37). These regulations concern
only commercial foods; breast milk cannot
be regulated, and fish or game caught by
individuals may be subject to advisories but
cannot be regulated. All these agentsarenow
unavoidable, in the sense that they are no
longer directly used and their appearance is
because of environmental contamination
or accident rather than current use.
Fortoxicityother than carcinogenicity, the
regulatory agencies use a safety factor
approach, in which the levels of exposure
thought to be associated with toxicity in
either humans or animals are divided by
some factors of ten, depending on the
uncertainty. For example, if the only data
available show toxicity at the lowest dose in
the experiment, or if there are no data
available for humans but only animal data, or
there is thought to be genetic varation in the
response, then the lowest observed effect
level (LOAEL) or the no-observed effect level
(NOAEL) is divided by 10 for each kind of
uncertainty to arrive at the reference dose,
the dose atwhich no morbidity is expected to
occur. Here we will work through the
safety factor approach for determining the
reference dose for PCBs, because sufficient
data exist to use human rather than animal
data. Taken together with data on food
consumption or other routes of exposure,
this would be one step toward arriving at
what levels of PCBs might be permitted in
specific foods orwhat exposure level from a
waste source requires intervention.
To estimate a reference dose for PCBs
from all sources, we estimate the dose to the
mother that results in the kinds ofPCB lev-
els that we now see, and use data from
observational studies ofPCB toxicity to get
the relationship between that maternal
exposure and morbidity in the child. There
are two studies of morbidity in children
occurring from background exposure PCBs
in the United States, one in central North
Carolina (the NC study) (38) and the other
near Lake Michigan (the MI study) (39).
Both were cohort studies in which mothers
were identified at or near term, the levels of
PCBs were measured in breast milk and
other fluids, and the children tested for
neurodevelopmental status over time. In
both studies, abnormalities ofdevelopment
were noted that bore a relationship to pre-
natal exposure rather than to exposure
through breast milk (40,41). Thus far,
these studies show morbidity from PCBs at
exposures lower than any other studies, and
so it is this morbiditywe wish to prevent by
limiting the mother's exposures.
Dose information is not available for the
women who participated in these studies,
and we need to make a number ofassump-
tions to estimate maternal dose (38). In the
NC study, the measure ofprenatal exposure
is the estimated amount of PCBs in the fat
ofbreast milkat term. Ifwe assume that this
breast milk fat is in steady state with the rest
of the body's fat, then we can calculate a
body burden, the mass of PCBs accumu-
lated bythe mother up to that point.
Neither the NC nor the MI data have
been modeled using techniques to estimate
thresholds of morbidity, and the linear
models used to control confounding
assume no threshold. For our purposes, we
therefore use the crude data, in which the
outcome variable (here, percent abnormals
or mean scores on various developmental
tests of children) is arrayed by level of
PCBs in milk fat (14,42) and estimate a
NOAEL by inspection. For the NC data,
that level appears to be about 3.4 ppm in
breast milk fat, and for the MI data, about
1.0 ppm. The estimated body burden of
PCBs in a theoretical 25-year-old, primi-
parous, 60-kg bw (U.S. median for 165-cm
tall female) (43), 25% body fat mother is
estimated body burden at NOAEL (mg)
= [av bw] x [av % body fat] x [NOAEL]
= 60 kg x 25% x 3.4 ppm
= 51 mg [1]
Ifwe assume that the mother accumu-
lated this body burden from equal daily
doses over her lifetime, that she has as her
only means of excretion either pregnancy
or lactation, and that she is primiparous,
then her daily dose associated with any
given level in breast milk is the body bur-
den at that level divided by age in days.
daily dose (mg/day)
body burden
age in days
51 mg
25 yearsx 365.25 days/year
= 5.6 x10-3mg/day
daily dose (mg/kg/day)
5.6 x10-3 mg/day
60kg
= 9.3x10-5 mg/kg/day [2]
Applicable safety factors would be
divided by 10 for variation in susceptibility
among exposed humans.
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reference dose (mg/kg/day)
daily dose (mg/kg/day)
safety factor
9.3x10-5 mg/kg/day
10
= 9.3x 10-6 mg/kg/day [3]
This yields a reference dose of
9.3 x 10- mg/kg/day; for 1.0 ppm in
milk fat, the reference dose would be
2.7 x 1o-6 mg/kg/day. In Table 1, we
briefly review PCB reference dose compar-
isons, including animal data and current
U.S. EPA estimates.
For comparison, the median concentra-
tion in breast milk fat in the MI data is
0.8 ppm, which would have been
achieved under these assumptions by a
daily dose of 2.2 x 10-5 mg/kg/day, an
order of magnitude above the refer-
ence dose. By an entirely different
method, involving analysis of foods com-
monly consumed in the United States (the
Market Basket Survey), FDA estimated
that dietary intake in the United States in
1978 was 3 x 10-5 mg/kg/day, but by 1982
was 3 x 10 mg/kg/day (44), essentially at
the estimated reference dose.
Thus, using human data on toxicity
and several assumptions concerning the
pharmacokinetics ofPCBs, we find that the
U.S. food supply, at least as it was in the
1960s and 1970s when the women in these
studies were growing up, provides no mar-
gin ofsafety for PCBs. This conclusion is
robust against most ofthe assumptions that
need to be made because some persons in
the population are already being affected;
thus, any process that seeks to prevent
morbidity in the population at large should
Table 1. Polychlorinated biphenyls reference dose comparison.
Type of effect
Rodents
Fetotoxicity; reproduction
Postnatal bodyweights
Motor activity
Learning and memory
Rhesus monkeys
Fetotoxicity; chloracne; postnatal bodyweights
Motor activity; learning/memory; performance
Humans
Developmental abnormalities (NC study)
Developmental abnormalities (Ml study)
Carcinogenicity, risk= 1 x 106
(U.S. EPAquantitative estimate, lifetime exposure)(56)
Current U.S. EPA reference dose
(based on low birthweight in rhesus monkeys) (56)
reach the conclusion that the extant levels
are too high. Ifwe had data only on work-
ers or persons with exceptional exposures
and were trying to extrapolate down to the
general population, the process would be
much more sensitive to the assumptions.
Risk of Cancer to the Child.
Historically, PCBs have been regulated
both as toxic substances without regard to
carcinogenicity and as carcinogens; in the
previous section, we estimated a dose to the
mother that would be expected to prevent
morbidity from occurring in the child as a
consequence ofprenatal exposure. In this
section, we attempt to estimate the risk to
the child posed by the presence ofcarcino-
genic substances in breast milk. All ofthese
agents are known or suspected carcinogens
in the laboratory. To estimate the exposure
forwhich the risk ofexcess cancer is consid- 6 ered minimal, usually one in 10 , the regu-
latory agencies use formal risk assessment
procedures that have their basis in the
mathematical modeling ofthe carcinogenic
process and the use of experimental data
from animals. We will work through the
estimate of the cancer risk for the nursed
infant for all the agents. Exposure to breast
milk cannot be regulated, but some esti-
mate ofthe degree oftoxicity expected from
the concentrations of chemicals that are
prevalent should help with questions about
the testing ofbreast milk and the interpre-
tation ofthe results ofthe tests.
The dose to the child consists of three
parts: the concentration of the chemical in
milk, the amount that the child consumes,
and the duration ofbreast feeding, i.e., the
time from birth until weaning. We use the
data of Savage et al. (45) for dieldrin
(another commonly found cyclodiene pesti-
cide), oxychlordane, and heptachlor epox-
Reference dose, mg/kg/daya
3.2 x 10-2
2.0 x 102
2.0 x104
1.0x 10-2
1.4 x 104
1.4x10-5
9.3 x106
2.7x1046
1.3 x 10-7
1.0x104
ide. We use the data of Rogan et al. for
PCBs and DDE (14). The data on TCDDs
(tetrachlorodibenzo-p-dioxins) are quite
sparse. We use data ofSchecter et al. (46),
which are based upon pooled samples; thus,
we cannot calculate percentiles. There are
very few data on the dibenzofurans, and no
bioassay data to estimate carcinogenicity,
and so we ignore the dibenzofurans for
these calculations.
We use the methods of Rogan and
Gladen (see below) to calculate the child's
typical dose ofPCBs and DDE (18,38). For
the other agents, we use the same method
but with a fixed rather than declining con-
centration over the course of lactation,
because the concentrations are much lower.
Using these methods, we estimate the dose
to the child from several combinations of
breast feeding durations and percentile con-
centrations ofchemicals (Table 2).
As an example ofthe procedure used to
estimate the child's exposure, we give the
detailed calculation for one of the PCB
combinations - the 90th percentile of
exposure for 9 months of breast feeding.
The 90th percentile for the concentration
of PCBs in breast milk is 2.97 ppm in fat
ofbreast milk (Table 2). To get the dose to
the child, we assume that breast milk is on
the average 2.5% fat and that the concen-
trations of PCBs decline by 20% in 6
months because ofthe chemical's excretion
into milk. The child drinks about 700 g of
milk per day. Total dose is the area under
the curve ofdaily dose versus days breast
fed. Daily dose is the concentration of
chemical in milk fat that day times milk
volume times the average percent fat in
breast milk. For PCBs, 9 months at the
90th percentile gives 12.4 mg total dose,
assuming first-order kinetics [an assump-
tion used by others (47) for dioxin].
Carcinogenicity. To estimate the excess
risk ofcancer from a given dose ofthese (or
any other) chemicals, we assume that risk is
some increasing linear function ofdose and
use an estimate of the slope of the dose-
response curve, which can be thought ofas a
potency. There are no data to allow us to
estimate the potency ofthese agents directly
in humans. The few experiments designed
specifically to evaluate the risk from expo-
sure through breast feeding do not provide
sufficient data to estimate potency (48,49);
there are, however, data from lifetime expo-
sure studies in laboratory animals. For all
but DDE, the U.S. EPA has conducted for-
mal risk assessments, and estimated an
upper bound on potency for lifetime expo-
sure to the agents in adult humans (50). For
DDE, we used a computer program,
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Table 2. Estimated excess risk of cancer by concentrations of chemicals and duration of breastfeeding.
Average
Concentration of daily dose, Excess risk (x 10-T) by
chemical in breastmilk, Total dose, mg mg/kg/day. duration and level of infantexposure
ppm (fat) 9 months q*, 9 months 6 weeks 3 months 6 months 9 months
Chemical 50th percentile 90th percentile 90th percentile mg/kg/day 90th percentile median 90th percentile median 90th percentile
DDE 2.51 5.33 21.5 0.5 1.3 x 10-4 0.96 3.65 2.63 6.99
Dieldrin < 0.01 0.12 0.6 20.0 3.6 x104 0.02 3.48 0.03 7.15
Heptachlor 0.01 0.10 0.5 9.1 3.0 x 104 0.08 1.32 0.24 2.71
Epoxide
Oxychlordane 0.03 0.10 0.5 1.3 3.1 x 10 0.03 0.20 0.08 0.41
PCBs 1.74 2.97 12.4 7.7 7.9x10'5 10.19 31.72 28.37 60.72
TCDD 5x104 2.1 xlO-5 156,000 1.4x10-10 0.56 1.04 1.65 2.14
(pooled sample) TOTAL 11.84 41.41 33.00 80.12
GLOBAL 82 (51), to extrapolate the results
ofthe National Cancer Institute DDEstudy
(52) to low doses using the methods ofthe
U.S. EPA (53). These techniques estimate
the 95% upper bound of the slope ofthe
dose-response curve, and adjust for inter-
species differences on the basis ofdifferences
in surface area. The potencies (convention-
ally called q*) are given in Table 2. The esti-
mated risks are for daily intake in milligrams
per kilograms bodyweight over alifetime.
There are numerous ways, but no
agreed upon method, to convert risks from
lifetime exposure in laboratory animals to
risks for short-term exposure in humans.
One way is to calculate the average differ-
ence over a lifetime in the exposure of a
breast-fed and nonbreast-fed child. This is
total dose from breast feeding averaged over
an effective lifetime (because ofthe latency
between exposure and the development of
cancer, exposure after some age is without
risk, because its consequences do not occur
in the life-span). We use 65 years for this
effective lifetime. Note that exposure to
these agents does not cease between the ter-
mination of breast feeding and 65 years;
however, the exposure is much lower and is
the same for both breast-fed and bottle-fed
children and thus does not enter into the
calculations ofexcess risk from breast feed-
ing. Similarly, we could base the analysis on
total lifetime dose rather than average daily
dose by changing the units ofthe potency
estimate. This allows for the fact that the
chemicals accumulate in the exposed organ-
ism. The results of these procedures are
excess lifetime cancer risks, ofunspecified
site and age at occurrence. For either expo-
sure estimate, we assume no synergy among
the compounds and simply add the excess
risks from all the contaminants.
To continue with the PCB example, to
get average daily dose, we divide total dose
(in milligrams) by the effective lifetime (in
days) and by interpolated median weight of
the child during 9 months ofbreast feeding
(54,55), which yields the dose on a mil-
ligram per kilogram basis during breast
feeding, and by the effective lifetime (in
days), as follows:
average daily dose (mg/kg/day)
total dose -_. effective lifetime median weight
during 9 months
ofbreastfeeding
12.4 mg
(365.25 days/year x 6.61 kg) 65 years
= 7.9 x 10-5 mg/kg/day [4]
An upper bound on the excess estimated
lifetime cancer risk based upon average daily
exposure is estimated by multiplying the
average daily dose by q* (Table 2); q* is
defined as the 95% upper bound of the
slope of the dose-response curve, as esti-
mated by the U.S. EPA. For PCBs, q* is
7.7 (mg/kg/day)-l. The estimated upper
bound on excess cancer risk in a lifetime
from 9 months ofbreast feeding at the 90th
percentile ofthe PCB distribution is then:
excess cancer riskdailydose
= av daily dosexq*
= 7.9x10-5mg/kg/day
x7.7 (mg/kg/day)-'
=61x10-5
[5]
To obtain risk based upon total dose,
we must first convert q* to units of mil-
ligram per kilogram-l instead ofmilligram
per kilogram per day-l. This is q* divided
by the length of the animal experiment in
days. Total dose is 12.4 mg, average weight
over a lifetime is 70 kg, and thus estimated
risk based on total dose is then
excess cancerrisktotaldose
length of animal experiment
total dose
x
av lifetime weight
7.7(mg/kg/day)-x 12.4 mg
- 2 years 70 kg
= 1.054x10-2(mg/kg)-l x0.177 mg/kg
= 186.7x10-5
[6]
Thus, excess risk based on total dose is
about three times higher than the estimate
based on average daily dose. Risk based on
total dose is not commonly used and
involves some extreme assumptions; we thus
present risks based on average daily dose in
Table 2. However, greater extremes are pos-
sible; we could assume that all risk from
short-term exposure comes from the first
exposure, which would magnify the risk by
about 2000-fold to a lifetime excess risk of
cancer of 16%, or about an 80% increase.
While this seems implausible, differences in
cancer risk ofthis magnitude are at about
the resolving power ofepidemiologic stud-
ies, and thus empirical confirmation ofthese
sorts ofcalculations within several orders of
magnitude are largely impossible.
Conclusion
Pharmacokinetic data, assumptions, and cal-
culations are necessary for either risk estima-
tion or standard setting. In the specific case
ofthe lactating woman, the environmental
toxicologist is usually in a different situation
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than that ofthe pharmacologist, because the
level in breast milk may be known, and it is
the dose that the mother might have gotten
that is unknown. In general, data are
unavailable with which to quantify precisely
absorption, distribution, persistence, etc.,
and guesses ofvarying degrees ofeducation
are required. Even in simple cases, the plausi-
ble range ofthese guesses may result in pre-
dictions that vary by several orders of
magnitude. The only responsible tactic in
such situations is to make all assumptions as
explicit as possible, estimate the sensitivity of
the conclusions to the assumptions, attempt
to use experimental data where it exists, and
recognize ignorance when it is found.
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